A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 650 participants.
Also called NCT02551874
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 650 participants
- Sponsor
- Registry
-
NCT02551874 -
2015-001702-33
-
- Other papers using this trial's data
- Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Denmark, Hungary, Mexico, Poland, Romania, South Africa, Spain, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT02551874. Randomized; no masking; primary purpose treatment. Start 2015-10-20 (actual); primary completion 2017-05-08 (actual). Results posted on 2018-09-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Saxagliptin, Onglyza
- Intervention (Drug)
- Dapagliflozin, Farxiga
- Intervention (Drug)
- Glargine insulin
- Intervention (Drug)
- Metformin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02551874- Content hash
bbd763f929a8ac29fceebb8eb43f90a0b48a20d314246ca34f9e5007cab5badd